Attorney Docket No. 021286-0272501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Force, et al	)	Examiner: NYA
Serial No:	10/040,244	)	Art Unit: 1644
Filed:	October 26, 2001	)	
Title:	ISOLATION AND CHARACTERIZATION OF HIGHLY ACTIVE ANTI-CD40 ANTIBODY	)	

Certificate of Mailing Under §1.8

I, Karyn F. Massie, hereby certify that this paper or fee is being deposited with the United States Postal Service as Regular Mail Post Office to Addressee service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Hon. Commissioner of Patents and Trademarks, Washington D.C. 20231 on March 20, 2003.

By: Karyn F. Massie
Karyn F. Massie

March 20, 2003

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Attached is Form PTO-1449 listing the enclosed citations submitted in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 03-3975, under the above Attorney Docket No., and proceed to consider this Information Disclosure Statement.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, in accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Applicant believes no fee is due at this time, however, if applicant is mistaken, the Assistant Commissioner of Patents is hereby authorized to charge any fees that may be necessary to Deposit Account No. 03-3975, Order No. 021286-0272501.

Respectfully submitted,

Date: 3-20-03

Robert M. Bedgood, Ph.D.
Registration No. 43,488

PILLSBURY WINTHROP LLP
11682 El Camino Real, Suite 200
San Diego, CA 92130
Telephone: (858) 509-4065
Fax Line: (858) 509-4010

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty. Dkt. No.	M#	Client Ref.
	021286-0272501	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Force, W., et al.

Appln. No.: 10/040,244

Filing Date: October 26, 2001

Date: March 20, 2003 Page 1 of 3

Examiner: NYA Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract Enclosed	English Abstract No	Translation Readily Available Enclose	Translation Readily Available No
	CR	WO 91/09115	06/1991	PCT	Banchereau		Y			
	DR	WO 96/33735	10/1996	PCT	Kucherlapati		Y			
	ER	WO 96/34096	10/1996	PCT	Kucherlapati		Y			
	FR	WO 99/61051	12/1999	PCT	Segal		Y			
	GR	WO 00/00156	01/2000	PCT	Wade		Y			
	HR	WO 00/75348 A1	12/2000	PCT	Siegall		Y			
	IR	WO 01/24823	04/2001	PCT	Keting		Y			
	JR	WO 01/56603	08/2001	PCT	Thomas		Y			
	KR	WO 02/28904	04/2002	PCT	Chu		Y			
	LR	EP 0945 465 A1	09/1999	EP	De Boer		Y			
	MR	EP 0972 445 A1	01/2000	EP	Tomizuka		Y			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	NR	Kwekkeboom, et al., "Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction," Eur. J. Immunol, (1994), Vol. 24, pp. 508-517.	Y
	OR	Hasbold, et al., "Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4," Eur. J. Immunol. (1998), Vol. 28, pp. 1040-1051.	Y
	PR	Pound, et al., "Minimal cross-linking and eptiope requirements for D40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotyic adhesions in human B cells," Int'l Immunol. (1999), Vol. 11, No. 1, pp. 11-20.	Y
	QR	Francisco, et al., "Agonistic Properties and *in Vivo* Antitumor of the Anti-CD40 Antibody SGN-14," Cancer Research, (June 15, 2000), Vol. 60, pp. 3225-3231.	Y
	RR	Romano, et al., "Triggering of CD40 Antigen Inhibits Fludarabine-Induced Aoptosis in B Chronic Lymphocytic Leukemia Cells," Blood, (August 1, 1998) Vol. 98, No. 3, pp. 990-995.	Y
	SR	Hirano, et al., "Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand," Blood, (May 1, 1999), Vol. 93, No. 9, pp. 2999-3007.	Y

	TR	Francisco, et al., "Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome –inactivating Protein Bryodin 1," Journal of Biological Chemistry, (Sept. 26, 1997), Vol. 272, No. 39, pp. 24165-24169.	Y			
	UR	Maxwell, et al., "Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity," J. Immunol., (May 1, 2002), Vol. 168, No. 9, pp. 4372-4381.	Y			
	VR	Simonsson, et al., "Single, Antigen-Specific B Cells Used to Generate Fab Fragments Using CD40-Mediated Amplification or Direct PCR Cloning," BioTechniques, (1995), Vol. 18, No. 5, pp. 862-869.				
	WR	Dullforce, et al., "Enhancement of T cell-independent immune responses *in vivo* by CD 40 antibodies," Nature Medicine, (Jan. 1998), Vol. 4, No. 1, pp.88 – 91.				
	XR	Erickson, et al., "Short-circuiting long-lived humoral immunity by the heightened engagement of CD40," The J. of Clinical Investigation, (March, 2002), Vol. 109, No. 5, pp. 613-620.				
	YR	Murphy, et al., "Antibodies to CD40 Prevent Epstein-Barr Virus- Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes," Blood, (September 1, 1995), Vol. 86, No. 5, pp. 1946-1953.	Y			
	ZR	Funakoshi, et al., "Differential In Vitro and In Vivo Antintumor Effects Mediated by Anit-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lyphomas," J. of Immunology, (1996) Vol. 19, No. 2, pp. 93-101.	Y			
	AAR	Schwabe, et al., "Modulation of Soluble CD40 Ligand Bioactivity with Anti-CD40 Antibodies," Hybridoma, (1997), Vol. 16, No. 13, pp. 217-226.	Y			
	BBR	Funakoshi, et al., "Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation," Blood, (May 15, 1994), Vol. 83, No. 10, pp. 2787-2794.	Y			
	CCR	Rolink, et al., "The SCID but Not the RAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching," Immunity, (October, 1996) Vol. 5, pp. 319-330.	Y			
	DDR	Kwekkeboom, et al., "CD40 plays and essential role in the activation of human B cells by murine EL4B5 cells," Immunology, (1993), Vol. 79, pp. 439-444.	Y			
	EER	Zhou, et al., "An Agonist Anti-Human CD40 Monoclonal Antibody that Induces Dendritic Cell Formation and Maturation and Inhibits Proliferation of a Myeloma Cell Line," Hybridoma, Vol. 18, No. 6, 1999, pp. 471-478.	Y			
	FFR	Heath, et al., "Monoclonal antibodies to murine CD40 define two distinct functional epitopes," Eur. J. Immunology, (1994) Vol. 24, pp. 1828-1834.	Y			
	GGR	Mazzei, et al., "Recombinant Soluble Trimeric CD40 Ligand Is Biologically Active," Journal of Biological Chemistry, (March 31, 1995), Vol. 270, No. 13, pp. 7025-7028.	Y			
	HHR	Hasbold, et al., "Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies," Eur. J. Immunology., (1994) Vol. 24, pp. 1835-1842.	Y			
	IIR	Weng, et al., "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," Program of the 43rd Annual Meeting of The American Society of Hematology, (December 7-11, 2001), Abstract No. 1947, page 466a.	Y			
	JJR	Ledbetter, et al., "Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5," Critical Reviews in Immunology, (1997), Vol. 17, pp. 427-435.	Y			
	KKR	de Boer, et al., "Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins," Journal of Immunological Methods, (1992) Vol. 152, pp. 15-23.	Y			
	LLR	Karlsson, et al., "Selection of human single chain antibodies against CD-40," Immunology Letters, Vol. 73, Nos. 2,3, Abstract No. 358.	Y			
	MMR	Sotomayor, et al., "Conversion of tumor-specific CD4 T-cell tolerance to T-cell priming through in vivo ligation of CD40," Nature, (July, 1999), Vol. 5, No. 7, pp. 780-787.	Y			

	NNR	Diehl, et al., "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy," Nature Medicine, (July 1999) Vol. 5, No. 7, pp. 774-779.	Y			
	OOR	Schoenberger, et al., "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," Nature, (June 4, 1998), Vol. 393, pp.480-483.	Y			
	PPR	van Mierlo, et al. "CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity," PNAS, (April 16, 2002) Vol. 99, No. 8, pp. 5561-5566.	Y			
	QQR	An, et al., "Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos – Burkitt Lymphoma B Cells," Cellular Immunology, (1997) Vol. 181, pp. 139-152.	Y			
	RRR	Barr, et al., "Functional activity of CD40 antibodies correlates to the position of binding relative to CD154," Immunology, (2001) Vol. 102, pp. 39-43.	Y			
	SSR	Baccam, et al., "Membrance-bound CD154, but not CD40-specific antibody, mediates NF-*x*B-independent IL-6 production in B cells," Er. J. Immunol., (1999), Vol. 29, pp. 3855-3866.	Y			
	TTR	Kedl, et al., "CD40 stimulation accelerates deletion of tumor specific CD8+ T cells in the absence of tumor-antigen vaccination," PNAS, (September 11, 2001) Vol. 98, No. 19, pp. 10811-10816.	Y			
	UUR	Tomizuka, et al., "Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and *k* loci and expression of fully human antibodies," PNAS, (January 18, 2000) Vol. 97, No. 2, pp. 722-727.	Y			
	VVR	Boon, et al., "Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys," Toxicology, (2002), Vol. 174, pp. 53-65.	Y			
	WWR					
	XXR					
	YYR					
	ZZR					

Examiner	Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.